目录产品 » HLA-A*03:01&B2M&gp100 (ALLAVGATK) Tetramer, His & Avi, Human
Manual
SDS
COAs

HLA-A*03:01&B2M&gp100 (ALLAVGATK) Tetramer, His & Avi, Human

Immunization against the ALLAVGATK peptide may occur in melanoma patients and that the immunogenicity of this peptide is similar to that of the majority of melanoma differentiation antigens defined to date. Therefore, the use of ALLAVGATK in active immunotherapy for HLA-A3 melanoma patients, for whom no other immunogenic peptide has been so far described, remains a distinct possibility, providing that patients treated in vivo with this peptide develop a better in vitro response than already demonstrated for HLA-A2 epitopes generated from this same antigenic protein
￥9900
Z06603-100

产品简介
Species Human
Protein Construction
HLA-A*03:01&B2M&gp100 (ALLAVGATK) Tetramer [Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and ALLAVGATK peptide]
Accession # NP_002107.3(HLA-A*03:01)&P61769(B2M)&ALLAVGATK		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background Immunization against the ALLAVGATK peptide may occur in melanoma patients and that the immunogenicity of this peptide is similar to that of the majority of melanoma differentiation antigens defined to date. Therefore, the use of ALLAVGATK in active immunotherapy for HLA-A3 melanoma patients, for whom no other immunogenic peptide has been so far described, remains a distinct possibility, providing that patients treated in vivo with this peptide develop a better in vitro response than already demonstrated for HLA-A2 epitopes generated from this same antigenic protein
Synonyms gp100 (ALLAVGATK)
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.